- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Richard J. Willke Discusses Challenges of Working With Real-World Data
When using real-world data, researchers must be careful to avoid several common pitfalls that can bias their results, according to Richard J. Willke, PhD, chief science officer of ISPOR.
When using real-world data, researchers must be careful to avoid several common pitfalls that can bias their results, according to Richard J. Willke, PhD, chief science officer of ISPOR.
Transcript (slightly modified)
What are the challenges of working with real-world data? Do the benefits outweigh the negatives?
There are usually 3 challenges in working with real-world data. One is careful data collection. “Garbage in, garbage out” applies here. Another is the lack of randomization, of course, and that’s where we have a lot of different study methods and analytic methods that can be applied to correct for confounding and selection biases. Another one that we’ve seen is that there tend to be a lot of results generated from real-world data, and some people call that data-dredging. The danger is to pay more attention to results that you like than what you don’t.
But, the benefits are that you can find out, as I said a minute ago, things that you can’t find out with randomized clinical trial data, how it actually performs in patients. So, it has to be viewed, as I said, in a complementary sense. How does the real-world data track versus the randomized controlled trial data, and then you try to make decisions about how they fit together.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
